Teacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Teacher Retirement System of Texas decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,602 shares of the biotechnology company's stock after selling 1,343 shares during the quarter. Teacher Retirement System of Texas' holdings in United Therapeutics were worth $3,577,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC raised its position in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after purchasing an additional 30 shares during the last quarter. Parallel Advisors LLC boosted its stake in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after acquiring an additional 30 shares in the last quarter. Anchor Investment Management LLC increased its position in United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after buying an additional 30 shares in the last quarter. Great Lakes Advisors LLC grew its position in United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares during the period. Finally, Florida Financial Advisors LLC lifted its position in United Therapeutics by 6.2% in the 4th quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after acquiring an additional 48 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director directly owned 1,750 shares of the company's stock, valued at approximately $499,747.50. This represents a 63.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,681 shares of company stock valued at $22,813,739 in the last 90 days. Insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on UTHR. UBS Group reduced their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Morgan Stanley upped their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $384.62.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $294.42 on Wednesday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The company's 50-day simple moving average is $300.95 and its 200 day simple moving average is $321.35. The firm has a market capitalization of $13.28 billion, a P/E ratio of 11.75, a PEG ratio of 6.36 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm posted $6.17 EPS. On average, equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.